Has Corey Miskevics received payments from drug or device companies?

Yes. Drug and device makers reported $2,907 in general payments to Corey Miskevics across 149 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Corey Miskevics did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Corey Miskevics come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Corey Miskevics

Psychiatric/Mental Health · Charlotte, NCNPI 1962183160

Payments from drug & device makers

$2,907in general payments, 2019–2025

Across 149 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Teva Pharmaceuticals USA, Inc.$432
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$390
Otsuka America Pharmaceutical, Inc.$382
Neurocrine Biosciences, Inc.$274
AbbVie$260
Lundbeck LLC$190
plus $980 from 16 others

What the payments were for

Food & beverage$2,79696%
Education$1114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Teva Pharmaceuticals USA, Inc.	21	$432
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	19	$390
Otsuka America Pharmaceutical, Inc.	13	$382
Neurocrine Biosciences, Inc.	20	$274
AbbVie	19	$260
Lundbeck LLC	11	$190
Johnson & Johnson	6	$131
E.r. Squibb & Sons, L.L.C.	6	$124
Bausch Health US, LLC	5	$108
Takeda Pharmaceuticals U.S.A., Inc.	5	$106
Vanda Pharmaceuticals Inc.	4	$76
Alkermes, Inc.	3	$73
Supernus Pharmaceuticals, Inc.	3	$69
Axsome Therapeutics, Inc.	2	$49
Corium, LLC	2	$47
Indivior Inc.	2	$44
Tris Pharma Inc	2	$42
Noven Therapeutics, LLC	2	$32
Collegium Pharmaceutical, Inc.	1	$23
Acadia Pharmaceuticals Inc	1	$22
Braeburn Inc.	1	$19
Almatica Pharma LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

REXULTI$117

How this compares

$2,907 in reported general payments places this provider in the 80th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Austedo XrDeutetrabenazine	15	$96,753
VraylarCariprazine Hcl	40	$60,446
Invega SustennaPaliperidone Palmitate	12	$39,592
RexultiBrexpiprazole	17	$28,748
LybalviOlanzapine/Samidorphan Malate	12	$20,873
AuvelityDextromethorphan Hbr/Bupropion	15	$16,188
BelsomraSuvorexant	25	$10,802
TrintellixVortioxetine Hydrobromide	12	$5,403
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	29	$3,180
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	62	$2,566
Lamotrigine ErLamotrigine	11	$1,956
Aripiprazole	21	$1,628
Lurasidone Hcl	33	$1,428
Prazosin Hcl	69	$1,083
Ziprasidone Hcl	14	$1,066

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr	$432	$96,75315 claims
AbbVieVraylar	$260	$60,44640 claims
Johnson & JohnsonInvega Sustenna	$131	$39,59212 claims
Otsuka America Pharmaceutical, Inc.Rexulti	$382	$28,74817 claims
Alkermes, Inc.Lybalvi	$73	$20,87312 claims
Axsome Therapeutics, Inc.Auvelity	$49	$16,18815 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix	$106	$5,40312 claims
Almatica Pharma LLCSertraline Hcl	$15	$15828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Charlotte

Desiree MatthewsCharlotte$807K
Benedetto PalomboCharlotte$671K
Carol Cameron MatthewsCharlotte$12K
Rohan MatthewsCharlotte$8K
Carli GastleyCharlotte$8K
Clarence RunnelsCreedmoor$339K
Lisa SuddrethGastonia$111K
April NandigamGreensboro$88K
Hannah NealeyFuquay Varina$75K
Jessica StoneRocky Mount$63K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →